Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091702 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
NCT00091702 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 300 participants.
The verdict
NCT00091702, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other people.
Interventions
- BIOLOGICAL Cold-adapted live attenuated influenza vaccine (FluMist)
- BIOLOGICAL Inactivated influenza vaccine (IAIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Est. Completion | 2006-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091702
The ClinicalTrials.gov registry entry for NCT00091702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cold-adapted live attenuated influenza vaccine (FluMist) is the first listed.
NCT00091702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091702 about?
NCT00091702 is a clinical study titled "Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents". The purpose of this study is to compare two flu vaccines to determine their safety and ability to stimulate an immune response in HIV infected children and adolescents. This study will also determine how often and how long people who receive a vaccine are able to spread flu vaccine virus to other pe...
What is the current status of trial NCT00091702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 300 participants. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00091702?
The interventions under investigation include: Cold-adapted live attenuated influenza vaccine (FluMist) (BIOLOGICAL), Inactivated influenza vaccine (IAIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00091702?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.